Quanterix Tech Stack
Ultra-sensitive biomarker detection platform moving from research to clinical diagnostics
Quanterix operates Simoa, an ultra-sensitive immunoassay platform used primarily in research settings across oncology, neurology, cardiology, and infectious disease. The company is actively transitioning from a research-focused business to in-vitro diagnostics (IVD), evident in a heavy project and pain-point load around regulatory submissions, assay validation, manufacturing scale-up, and reimbursement—paired with accelerating sales hiring. Their tech stack is clinical-grade (LIMS, Azure, Microsoft Defender, Sentinel) rather than software-forward, reflecting a regulated-biology company managing sample workflows and compliance.
Tech Stack 36 technologies
What Quanterix Is Building
◆Challenges
- Finding new customers
- Sample shipment delays
- Reducing manufacturing quality issues
- Scaling up reagent manufacturing
- Expanding into ivd validation
- Regulatory compliance for ivd submissions
- Risk assessment and mitigation
- Design control compliance
- Revenue recognition compliance
- Billing reimbursement optimization
▲Active Projects
- Regulatory submissions for eu ivdr and fda 510(k)
- Accelerator qms implementation
- Risk assessment of systems and infrastructure
- Reagent process development for ivd and ruo products
- Deployment of analytical test systems
- Ivd validation of simoa biomarker assays
- Transfer assays to manufacturing
- Diagnostics business launch
- Billing reimbursement optimization
- Revenue contract analysis
Hiring Activity
Department
Seniority
Notable leadership hires: Lead Generation Manager, Lead Generation Specialist, Global Events Lead